Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ALZT-OP1 (cromolyn + ibuprofen) in early Alzheimer's disease
2015-002147-34Phase 3Completed
- Sponsor
- AZTherapies
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium cromoglycate and ibuprofen in Alzheimer's disease (AD) (3 arms), sponsored by AZTherapies. Started Oct 2015; status: completed.
02
Drugs
sodium cromoglycateibuprofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-002147-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002147-34.